Intrommune Therapeutics
PrivateLast Round
Series A
Jun 9, 2021
Est. Valuation
$15.11M
Total Funding Raised
$5.51M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Intrommune Therapeutics is a biotechnology company that is developing a treatment platform for food allergies using oral mucosal immunotherapy (OMIT) delivered through a specially formulated toothpaste.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Medical Devices
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Intrommune Therapeutics Comparables
Compare Intrommune Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Moonlight Therapeutics | 81% | |
| Prota Therapeutics | 78% | |
| InnoUp Farma | 78% |
Intrommune Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 9, 2021 | ||||
| Crowdfunding | Apr 12, 2018 |
Intrommune Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Chemical Angel Network | Series A |
| Robin Hood Ventures | Series A |
| Red Bear Ventures | Series A |
| Timberline Holdings | Series A |
| Netcapital | Crowdfunding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Web traffic grew 31% MoM (from 1.5K to 1.9K monthly visitors)
- Jul 25, 2026
Monthly visitors increased 37% MoM.
Intrommune Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Intrommune Therapeutics's valuation, stock price, and market status.
Is Intrommune Therapeutics a public or private company?
Intrommune Therapeutics is a private company.
What is the current stock price of Intrommune Therapeutics?
Intrommune Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Intrommune Therapeutics worth (valuation)?
Intrommune Therapeutics's valuation is estimated at $15.1M based on funding round data.
Can I buy Intrommune Therapeutics stock?
Intrommune Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Intrommune Therapeutics's last funding round?
Intrommune Therapeutics's most recent funding round was Series A on April 12, 2018.
Who are the main investors in Intrommune Therapeutics?
Key investors in Intrommune Therapeutics include Red Bear Ventures.
Will Intrommune Therapeutics IPO soon?
No public IPO plans have been announced for Intrommune Therapeutics.
How can I track Intrommune Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Intrommune Therapeutics's secondary market activity and sign up for updates.